Saturday 17 October 2026
Export TLSI’s income statement to Excel — free account
TriSalus Life Sciences, Inc.
TLSI Healthcare Medical Devices
TriSalus Life Sciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $45.2 million, up 53.4% from fiscal 2024. In the quarter to June 2026, revenue grew 1.73%, EPS grew 40.7%, free cash flow fell 41.3% and total debt rose 2.45%, each against the same quarter a year earlier. Revenue growth for three consecutive years; insiders bought in the last twelve months.
3.63
0.27
−6.92%
Follow TLSI
| Dec '17 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|
P/E ratio |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 |
Piotroski F-Score |
— | — | — | — | — | 4 | 3 |
Altman Z-Score |
— | — | — | (17.58) | (19.53) | (18.03) | (11.34) |
P/S ratio |
— | — | — | 0.00 | 4.19 | 4.31 | 5.86 |
Altman Z″-Score (non-manufacturers) |
— | — | — | (44.20) | (46.85) | (45.84) | (32.29) |
P/FCF ratio |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 |
Beneish M-Score |
— | — | — | — | (3.28) | (0.34) | (5.08) |
P/Operating CF |
— | — | — | (0.37) | (8.45) | (22.24) | (106.49) |
P/B ratio |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 |
Price to Tangible BV |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Sales |
— | — | — | 0.00 | 3.64 | 4.78 | 6.14 |
EV/EBITDA |
— | — | — | 0.11 | 0.00 | 0.00 | 0.00 |
EV/Operating CF |
— | — | — | 0.12 | (1.33) | (3.45) | (15.40) |
EV/FCF |
— | — | — | 0.12 | (1.30) | (3.36) | (14.16) |
Quick Ratio |
— | 12.94 | 0.13 | 0.34 | 1.04 | 1.33 | 2.35 |
Current Ratio |
— | 19.46 | 0.33 | 0.53 | 1.42 | 2.02 | 2.80 |
Net Debt/EBITDA |
— | 12.30 | (0.11) | 0.22 | 0.22 | (0.39) | (0.50) |
Debt/Assets |
0.00% | 0.00% | 0.22% | 6.10% | 0.00% | 92.13% | 93.53% |
Debt/Equity |
— | 0.00 | (0.03) | (0.01) | 0.00 | (0.85) | (0.98) |
Asset Turnover |
— | 0.00 | 0.00 | 0.09 | 0.79 | 1.21 | 1.52 |
Operating CF/Net income |
— | 0.95 | (0.36) | 0.65 | 0.80 | 1.23 | 0.26 |
Capex/Depreciation |
— | — | — | (1.97) | (1.64) | (0.25) | (0.50) |
Interest Coverage |
— | (32.88) | (47.51) | (36,439.00) | (3,404.69) | (11.70) | (4.86) |
| — | (0.60%) | (24.96%) | 51.82% | 62.54% | 125.50% | 233.25% | |
| — | (0.56%) | 1.90% | (36.71%) | (273.01%) | (136.85%) | (235.03%) | |
ROIC |
— | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
— | (37.34%) | (443.18%) | 387.36% | (769.44%) | (274.43%) | (309.01%) |
Average Days of Receivables |
— | — | — | 45.84 | 70.08 | 63.09 | 53.01 |
Research and Development Expense of Revenue |
— | — | — | 172.27% | 161.17% | 60.10% | 33.14% |
Selling, General and Administrative Expense of Revenue |
— | 0.00% | 0.00% | 203.43% | 219.04% | 148.84% | 111.11% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.04 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
— | — | — | 2.97% | 7.57% | 18.49% | 20.22% |
Graham Net Nets |
— | — | — | (58.13) | (0.40) | (0.23) | (0.14) |
Graham Number |
— | — | — | 1,395.74 | 46.62 | 5.53 | 6.07 |
Earnings Yield |
— | — | — | (1,514.59%) | (406.46%) | (26.55%) | (26.22%) |
Free Cash Flow Yield |
— | — | — | (1,058.19%) | (66.96%) | (33.04%) | (7.40%) |
Revenue per Share |
— | 0.00 | 0.00 | 39.99 | 1.97 | 1.16 | 1.19 |
Operating CF per Share |
— | (0.11) | (0.28) | (104.24) | (5.38) | (1.61) | (0.48) |
Capex per Share |
— | 0.00 | 0.00 | (2.54) | (0.12) | (0.01) | (0.02) |
Free Cash Flow per Share |
— | (0.11) | (0.28) | (106.77) | (5.50) | (1.63) | (0.50) |
Cash per Share |
— | 0.21 | 0.03 | 30.37 | 1.25 | 0.34 | 0.54 |
Shareholders Equity per Share |
— | (3.40) | (2.67) | (568.81) | (2.88) | (1.02) | (0.89) |
Interest Debt per Share |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
— | (3.40) | (2.67) | (568.81) | (2.88) | (1.02) | (0.89) |
Free Cash Flow |
— | (0.68) | (1.74) | (33.10) | (51.70) | (41.19) | (18.85) |
Working Capital |
— | 1.91 | (1.08) | (15.14) | 6.18 | 10.44 | 20.75 |
Capital Expenditures |
— | — | — | (0.79) | (1.12) | (0.34) | (0.84) |
Net Current Asset Value |
— | (271.49) | (266.72) | (181.11) | (30.80) | (29.20) | (36.95) |
EV/EBIT |
— | — | — | 0.11 | 0.00 | 0.00 | 0.00 |
Capex to Sales |
— | — | — | 0.06 | 0.06 | 0.01 | 0.02 |
Price to Operating Income |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | |||||||
Depreciation/Fixed assets |
— | — | — | 0.18 | 0.33 | 0.81 | 0.93 |
Cash ROIC |
— | 3.36% | 10.88% | 19.99% | 338.17% | (873.55%) | (96.06%) |
Accounts Receivable Turnover |
— | — | — | 0.00 | 7.24 | 6.81 | 7.75 |
Accounts Payable Turnover |
— | — | — | 0.75 | 0.62 | 1.45 | 2.64 |
Inventory Turnover |
— | — | — | 0.00 | 1.30 | 1.24 | 1.96 |
Average Days of Payables |
— | — | 0.00 | 799.67 | 475.13 | 202.29 | 157.32 |
Days of Inventory on Hand |
— | — | — | 237.78 | 356.59 | 360.11 | 161.25 |
Average Receivables |
— | — | — | — | 2.56 | 4.32 | 5.82 |
Average Payables |
— | — | — | 3.00 | 4.17 | 2.83 | 2.64 |
Average Inventory |
— | — | — | — | 2.01 | 3.30 | 3.56 |
Average Assets |
— | 126.01 | 251.27 | 136.26 | 23.30 | 24.28 | 29.65 |
Average Common Equity |
— | 119.14 | (19.10) | (96.52) | (101.70) | (26.48) | (29.88) |
Columns are period end dates